eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
Eyenovia, Inc. Announces Closing of Offering of Common Stock
Upcoming Events
There are currently no events scheduled.